HD therapies

Key therapies

At NephroCare we aim to provide all of our patients with the best possible therapy according to their individual needs and physical condition. As such, we offer different forms of haemodialysis:

High-Flux dialysis

The essential element of High Flux Dialysis is the use of dialysers that have larger pores for the removal of both uraemic toxins and fluid. In conventional dialysis waste products and electrolytes are removed from the patient’s blood by diffusion – the movement of solutes from a solution of higher concentration (blood) to one of lower concentration (the dialysate) across a semipermeable membrane. Blood urea nitrogen (BUN) is measured and followed as a reflection of all the toxins that the kidney normally removes. With High Flux Dialysis, BUN is clearly removed more quickly. Larger molecules are too big to be removed by conventional dialysis, but are removed with high flux dialysers.


HighVolumeHDF® with its numerous positive effects on dialysis-related cardiovascular risk factors is acknowledged as the most effective dialysis treatment modality , coming closer to the elimination profile of the natural kidney.

By achieving high substitution volumes, HighVolumeHDF® therapy is credited with more effective elimination of middle molecules. HighVolumeHDF® improves patient outcomes and exerts beneficial effects on the main cardiovascular risk factors:

  • Serum ß2-microglobulin and phosphate level2,3,4
  • Inflammatory response5
  • Intradialytic haemodynamic stability6
  • Anaemia control7

These factors contribute to better quality of life and improved patient survival.8

Optimising therapies for improved outcomes

Achieving optimal outcomes means addressing cardiovascular risk factors in dialysis patients.

Use of advanced therapies such as High-Flux dialysis or HighVolumeHDF®, taken together with fluid management, improves outcomes, leading to:

  • reduced mortality risk
  • fewer cardiovascular complications
  • optimised use of resources

Fewer cardiovascular complications - Reduction of inflammation

Inflammation is an important cardiovascular risk factor for dialysis patients. Serum levels of inflammatory markers such as cytokines and C-reactive protein (CRP) are higher in these patients than in the general population. CRP has been identified as a predictor of all-cause and cardiovascular mortality in patients on haemodialysis.

Patients being treated with HDF benefit from significantly lower levels of CRP than patients on Low-Flux HD.